Is there a rationale for the prophylactic prescription of hematopoietic colony-stimulating factor after a bacteriologically documented neutropenic infection?
Thieblemont
C
C
Frappaz
D
D
Coullioud
D
D
Fuhrmann
C
C
Bouffet
E
E
Brunat-Mentigny
M
M
Philip
T
T
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects; D001424:Bacterial Infections / Q000453:epidemiology / Q000209:etiology* / Q000517:prevention & control; D005334:Fever / Q000209:etiology; D005602:France / Q000453:epidemiology; D016298:Hematopoietic Cell Growth Factors / Q000627:therapeutic use*; D006801:Humans; D016867:Immunocompromised Host; D015994:Incidence; D009369:Neoplasms / Q000150:complications / Q000188:drug therapy; D009503:Neutropenia / Q000139:chemically induced / Q000150:complications / Q000188:drug therapy*; D012189:Retrospective Studies; D018805:Sepsis / Q000453:epidemiology* / Q000209:etiology / Q000517:prevention & control
D016298:Hematopoietic Cell Growth Factors